CHMP Backs Combo Drug Orkambi for Cystic FibrosisCHMP Backs Combo Drug Orkambi for Cystic Fibrosis

Orkambi combines lumacaftor and ivacaftor and is indicated for patients with CF aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene. International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news